b'Results (contd) Conclusions Among 1283 biologics-naive patients during the 6-month pre-index period, 1184 Within the 6 months following ruxolitinib cream(92.3%) did not receive biologics during the 6-month follow-up period(Table 2) initiation, there was a decrease in utilization of Among 298 patients who received biologics in the 6-month pre-index period, other AD treatments52 (17.4%) did not continue biologics during the 6-month follow-up period Almost half of the patients did not receive any other AD treatmentFigure 3. Oral Corticosteroid Use Before and After Initiation of Ruxolitinib CreamBoth topical and oral corticosteroid use decreased Over 90% of biologics-naive patients did not initiate biologics, and 17.4% of patients who were on biologics during the 6-month pre-index perioddid not continue these treatments during the 6-month follow-up period Thus, early assessments suggest that initiatingruxolitinib cream may reduce the overall need forother AD therapies such as topical/oral corticosteroidsand biologicsDisclosuresJL and DS are employees and hold stock and/or stock options in Incyte Corporation. KD, C-CT, GS, and VW are employees of Carelon Research, which received funding from Incyte to perform this research.AcknowledgmentsThe study was funded by Incyte Corporation (Wilmington, DE, USA). Writing assistance was provided by Mitali Choudhury, PhD, an employee of ICON (Blue Bell, PA, USA), and was funded by Incyte.Table 2. Biologics Use for AD Before and After Initiation of Ruxolitinib Cream References 1. Langan SM, et al. Lancet. 2020;396(10247):345-360. 2. Barbarot S, et al. Allergy.2018;73(6):1284-1293. 3. Anderson P, et al. Dermatol Ther. 2021;11(5):1571-1585.4. OPZELURA (ruxolitinib cream). Full Prescribing Information, Incyte Corporation,Wilmington, DE, 2022. 5. Papp K, et al. J Am Acad Dermatol. 2021;85(4):863-872.6. Papp K, et al. J Am Acad Dermatol. 2023;88(5):1008-1016.'